Advertisement
UK markets closed

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • CRUDE OIL

    82.60
    -0.76 (-0.91%)
     

  • GOLD FUTURES

    2,336.80
    -5.30 (-0.23%)
     

  • DOW

    38,527.92
    +24.23 (+0.06%)
     

  • Bitcoin GBP

    52,065.45
    -1,540.88 (-2.87%)
     

  • CMC Crypto 200

    1,403.68
    -20.42 (-1.43%)
     

  • NASDAQ Composite

    15,739.36
    +42.72 (+0.27%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

How the Market Reacted to Teva’s Pricing of Its Generic Syprine

Sarah Collins
Updated
How the Market Reacted to Teva’s Pricing of Its Generic Syprine

On February 9, 2018, Teva Pharmaceutical (TEVA) announced the US launch of its generic version of 250 mg Syprine capsules. Syprine capsules are trientine hydrochloride tablets, which are used for the treatment of penicillamine-intolerant patients suffering from Willson’s disease. Willson’s disease is a rare genetic disorder characterized by excessive copper in the body due to the body’s incapability to remove it, which can lead to life-threatening organ damage. According to the National Institute of Health, one in 30,000 people in the United States suffer from Willson’s disease.

Continue reading